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PharmacokineticsAbstract Background: Although albendazole is the drug-of-choice for the treatment of neurocys-
ticercosis, its efficacy is limited due to its low bioavailability. An alternative for optimizing pharma-
cological treatment is through drug combinations. In vitro studies have shown that nitazoxanide
and tizoxanide (the active metabolite of nitazoxanide) exhibit cysticidal activity and that the com-
bination of tizoxanide with albendazole sulfoxide (the active metabolite of albendazole) produced
an additive effect. Objectives: (1) To assess the concentration profile of tizoxanide in plasma and in
cerebrospinal fluid; and (2) to evaluate the influence of nitazoxanide on the pharmacokinetics of
albendazole in plasma and in cerebrospinal fluid. Methods: Two different studies were conducted.
In study 1, 10 male Sprague-Dawley rats received a single oral dose of 7.5 mg/kg of nitazoxanide
and serial blood and cerebrospinal fluid samples were collected over a period of 4 h. In study 2,
38 healthy male Sprague-Dawley rats were randomly divided into two groups: one of these received
a single dose of albendazole (15 mg/kg) and, in the other group, albendazole (15 mg/kg) was co-
administered with nitazoxanide (7.5 mg/kg). Plasma and cerebrospinal fluid samples were collected
from 0 to 16 h after administration. Albendazole sulfoxide and tizoxanide levels were assayed byy 04510,
.edu.mx
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Pharmaceutical Journal (2016), http://dx.doiusing HPLC or LC/MS techniques. Results: In study 1, tizoxanide reached a maximum plasma con-
centration of 244.42 ± 31.98 ng/mL at 0.25 h; however, in cerebrospinal fluid, this could be
detected only at 0.5 h, and levels were below the quantification limit (10 ng/mL). These data indi-
cate low permeation of tizoxanide into the blood brain barrier. In study 2, Cmax, the area under the
curve, and the mean residence time of albendazole sulfoxide in plasma and cerebrospinal fluid were
not affected by co-administration with nitazoxanide. Conclusion: The results of the present study
indicate that in rats at the applied doses, tizoxanide does not permeate into the cerebrospinal fluid.
Furthermore, nitazoxanide does not appear to alter significantly the pharmacokinetics of albenda-
zole in plasma or in cerebrospinal fluid.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neurocysticercosis (NCC) is the most important parasitic
infection of the nervous system caused by the larval form of
the tapeworm Taenia solium. The infection is acquired when
a human ingests oncospheres of Taenia, which permeate into
the small blood vessels and migrate to muscles, brain, and
other tissues (Nash and Garcia, 2011). NCC is the major cause
of seizures and a public health problem in many countries of
the Indian subcontinent and Latin America, including Mexico
(Fleury et al., 2012; Ndimubanzi et al., 2010). Pharmacological
treatment of NCC is based on two cysticidal drugs: praziquan-
tel (PZQ) and albendazole (ABZ). Given its efficacy, to date
ABZ is preferred over PZQ (Del Brutto et al., 2006). ABZ
binds to the b-subunit of tubulin, inhibiting its polymerization,
thus preventing microtubule formation (Lacey, 1990; Martin,
1997).
ABZ is rapidly and extensively metabolized to albendazole
sulfoxide (ABZ-SO), an active metabolite. In humans, the
metabolite permeates into the cerebrospinal fluid (CSF); how-
ever, due to the low solubility of ABZ, its bioavailability is low
and variable, and therefore plasma and CSF levels of ABZ-SO
are also highly variable among individuals (Jung-Cook, 2012).
In order to increase ABZ bioavailability, different strategies
have been proposed during the last 10 years: for example,
administration of ABZ with a fatty meal (Mares et al.,
2005), use of surfactants in solid dispersions (Castro et al.,
2013), the development of binary and ternary formulation sys-
tems with cyclodextrins, as well as the use of water soluble
polymers or hydroxyacids (Casulli et al., 2006; Kalaiselvan
et al., 2006, 2007; Palomares-Alonso et al., 2010). Recently,
a novel intranasal microemulsion has been evaluated for the
delivery of ABZ-SO to the brain (Shinde et al., 2015). Despite
the positive results reported, none of them is available in the
market.
The combination with existing drugs offers another alter-
native for increasing ABZ effectiveness. Little research has
been performed in this area, and the majority of the studies
are related to the ABZ–PZQ combination. For example, an
in vitro additive interaction between PZQ and ABZ-SO was
reported by our group (Palomares et al., 2006). It has also
been demonstrated that plasma levels of ABZ-SO increased
when the combined treatment was administered in patients
with NCC (Garcia et al., 2011). Recently, the same authors
documented that this combination was more effective than
ABZ alone in patients with parenchymal NCC (Garcia
et al., 2016).do, M.I. et al., Eﬀect of nitazoxanide on
.org/10.1016/j.jsps.2016.09.005Another drug that has demonstrated activity against differ-
ent nematodes and trematodes is nitazoxanide (NTZ)
(Anderson and Curran, 2007; van den Enden, 2009). This drug
is used as a broad-spectrum antiparasitic drug in adults and
children in many areas of the world (Somvanshi et al., 2014).
Also, this drug has demonstrated cysticidal efficacy against
Taenia crassiceps cysts (Palomares-Alonso et al., 2007). After
its oral administration, NTZ is partially absorbed from the
gastrointestinal tract and is rapidly hydrolyzed by plasma
esterases into its desacetyl derivative, tizoxanide (desacetyl-
nitazoxanide, TZO) which is the active metabolite (Stockis
et al., 1996). Although its mechanism of action is not well
known, it has been postulated that in helminths, NTZ is a
non-competitive inhibitor of the pyruvate ferredoxin oxidore-
ductase enzyme, altering anaerobic metabolism (Romero
et al., 1997; Walker et al., 2004).
Considering that the mechanisms of action of NTZ and
ABZ are different, this combination has been evaluated for
the treatment of echinococcosis and cysticercosis. Thus,
Stettler et al. (2004) found that the use of NTZ in combination
with ABZ improved the ABZ pharmacokinetics as well as effi-
cacy in the echinococcosis murine model. In the case of cys-
ticercosis, Palomares-Alonso et al. (2007) reported that the
combination of NTZ and ABZ, as well as ABZ-SO and
TZO, resulted in an additive effect against Taenia crassiceps
cysts in vitro.
Taking into account that one of the major obstacles to suc-
cessful pharmacological management of NCC is the presence
of the blood brain barrier (BBB) (Nau et al., 2010), the present
study attempted to determine whether TZO is capable of cross-
ing the BBB and to evaluate the influence of NTZ on the phar-
macokinetics of ABZ in plasma and in CSF.
2. Materials and methods
2.1. Chemicals and reagents
ABZ-SO and TZO standards used for the analytical methodol-
ogy were synthesized by Drs. Rafael Castillo-Bocanegra and
Alicia Herna´ndez Campos at the Facultad de Quı´mica,
UNAM, Mexico. Chemical identity was confirmed by NMR,
MS analysis, and melting point determination. ABZ, meben-
dazole (MBZ), and nifuroxazide (NFZ), used as internal stan-
dards (IS) for plasma ABZ-SO and plasma TZO analysis,
respectively, were purchased from Sigma-Aldrich Co. (St.
Louis, MO, USA). Methanol, acetonitrile, ether, dichloro-
methane, and chloroform were of HPLC grade (Mallinckrodtalbendazole pharmacokinetics in cerebrospinal ﬂuid and plasma in rats. Saudi
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St. Louis, MO, USA) was of analytical reagent-grade. Water
was obtained from a Milli-Q Water System (Millipore Corpo-
ration, Bedford, MA, USA).
For the pharmacokinetic studies, ABZ suspension (Zen-
tel, 400 mg/10 mL; Glaxo SmithKline) and NTZ suspension
(Paramix, 100 mg/5 mL; Liomont Laboratories) were used.
2.2. Animal experiments
2.2.1. Animal care and surgery
Male Sprague-Dawley rats weighing 305 ± 15 g were pur-
chased from Harlan (Harlan, Mexico City, Mexico). The ani-
mals were housed one per cage and were maintained at a
temperature of 18–23 C and at 40–70% relative humidity
under 12-h light:12-h dark cycles. Food and water were freely
available. The study protocol complied with the Guide to the
Care and Use of Experimental Animals and was approved
by the Animal Care Committee of the Instituto Nacional de
Neurologı´a y Neurocirugı´a (INNN) (Mexico City, Mexico).
For the cannulation procedure, each animal was anes-
thetized by an intraperitoneal injection of Ketamine (50 mg/
kg) and Xylazine (10 mg/kg).
2.2.1.1. CSF collection. Animals were cannulated in cisterna
magna using the technique reported by Consiglio and Lucion
(2000). Briefly, rats were anesthetized as described previously
and the surgical region was shaved. The animal was immobi-
lized in a stereotaxic apparatus and an incision was made on
the top of the head. The stereotaxic parameters for cannulating
the rat were the following: antero-posterior (AP) = 2.7 mm
(posterior to the interaural line); vertical (V) = 6.2 mm
(below the dura mater); lateral = 0, and superior inci-
sive = 3.2 mm under the interaural line. Once the system
was localized, trepanation was performed. A stainless steel
tube 1 cm in length with 23-G thickness with a rounded tip
was inserted with an inclination of 31, 2 mm in depth, and
fixed with dental cement. Rats were allowed to recover from
anesthesia for a period of 48 h.
2.2.1.2. Plasma collection. Rats were cannulated in the lateral
tail vein under anesthesia following a procedure that was pre-
viously described by de Jong et al. (2001). An incision was
made 3 cm from the tail base and the vein was exposed; a pre-
viously heparinized polyethylene cannula (ID 0.023 in and OD
0.038 in) (Becton Dickinson, Franklin Lakes, NJ, USA), was
introduced and fixed with a 2–0 surgical suture. The animals
were left to recover for a period of 1–3 h prior to the pharma-
cokinetic study. During the study, the animals received water
ad libitum.
2.2.2. Pharmacokinetic studies
The study was divided into two different experiments. In the
first experiment, the objective was to assess TZO permeation
through the BBB. In this study, plasma and CSF pharmacoki-
netics was evaluated. In the second experiment, the pharma-
cokinetic effect of concomitant administration of ABZ and
NTZ in plasma and the CSF pharmacokinetic profile of
ABZ-SO were studied. For NTZ, a 7.5 mg/kg dose was
selected according to the dose used in humans for the treat-
ment of diarrhea associated with Giardia lamblia or Cryp-Please cite this article in press as: Ruiz-Olmedo, M.I. et al., Eﬀect of nitazoxanide on
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.09.005tosporidium parvum; in addition, this dose has been proposed
for the treatment of mixed parasitic infections (protozoa and
helminths) (Romero et al., 1997; Fox and Saravolatz, 2005).
For ABZ, we selected the dose employed for NCC treatment
in humans (15 mg/kg) (Jung-Cook, 2012).
2.2.2.1. Study 1. Pharmacokinetic study of TZO. Ten rats were
administered orally with a dose of 7.5 mg/kg of NTZ. Plasma
and CSF samples (three blood samples of 0.6 mL, and three
CSF samples of 20 lL per animal) were obtained at 0,
15 min, 30 min, 1 h, 2 h, and 4 h after drug administration
(with five replicates per sampling time). Blood samples were
collected in heparinized tubes and centrifuged at 3,000 rpm
for 10 min. Plasma and CSF samples were stored at 70 C
until analysis.
2.2.2.2. Study 2. Effect of NTZ on ABZ pharmacokinetics in
plasma and in CSF. Rats were randomly assigned to two treat-
ment groups (n= 19 each): In Group I, the animals received a
single dose (15 mg/kg) of ABZ, and in group II, the animals
received ABZ and NTZ in combination (15 mg/kg + 7.5 mg/
kg, respectively). Drugs were orally administered. Blood and
CSF samples (three blood samples and three CSF samples
per animal) were collected at 0, 15 min, 30 min, 1 h, 2 h, 4 h,
8 h, 10 h, 12 h, 14 h, and 16 h after drug administration (with
five replicates per sampling time).
2.3. Drug assays
Complete validation of the analytical procedures for drug
quantitation was performed before the pharmacokinetic stud-
ies. For preparation of calibration curves as well as quality
controls and blank samples, rat plasma and artificial CSF were
used. Artificial CSF was prepared with NaCl (125 mM), KCl
(2.5 mM), MgCl2 (1.18 mM), and CaCl2 (1.26 mM) dissolved
in 1.5 L of phosphate-buffered saline (PBS) solution pH 4
(Na2HPO4 2.97 mM, and NaH2PO4 1.06 mM).
2.3.1. Plasma and CSF quantitation of TZO
The chromatographic system (Waters, Milford, MA, USA)
consisted of a Model 2690 Waters Alliance HPLC pump, with
a Model 2996 photodiode array detector (set at 416 nm) and a
Model 2690 Waters Alliance autosampler (set at 15 C)
equipped with a 100-lL loop. Chromatographic separation
was performed using an X-Terra C18 analytical column
(150  4.6 mm, 5 lm; Waters) attached to a pre-column (Phe-
nomenex C18 ODS). The column oven was maintained at
25 C. A ternary gradient was used for the chromatographic
separation. The initial mobile phase was composed of KH2PO4
50 mM buffer (pH 5.7):methanol:acetonitrile (90:5:5, v/v/v). A
linear gradient was achieved varying the mobile-phase compo-
sition during 23 min up to the final mixture, KH2PO4 50 mM
buffer (pH 5.7):methanol:acetonitrile (10:45:45, v/v/v). For
plasma analysis, a previously published technique was
employed (Ruiz-Olmedo et al., 2009). Plasma samples
(200 lL) were spiked with 100 lL of NFZ (6,000 ng/mL) as
IS. After the addition of 200 lL of acetonitrile for protein pre-
cipitation, samples were vortex-mixed for 2 min and cen-
trifuged at 15,000 rpm for 20 min. Supernatant was obtained
and 100 lL was injected into the chromatographic system.
CSF samples (20 lL) were analyzed without any pre-albendazole pharmacokinetics in cerebrospinal ﬂuid and plasma in rats. Saudi
Table 1 Gradient for ABZ-SO analysis in CSF samples.
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Figure 1 Tizoxanide plasma concentration time profile after an
oral dose of 7.5 mg/kg nitazoxanide. Each point represents the
mean ± SD, n= 5.
4 M.I. Ruiz-Olmedo et al.treatment steps by using the external calibration method in
artificial CSF. Calibration curves for both fluids were con-
structed by least-squares linear regression with correlation
coefficients of P0.998. For plasma, the method was linear
within a range of 20–1280 ng/mL; the method was precise (rel-
ative standard deviation, RSD, <8%) and accurate (absolute
deviation, <8%). In the case of CSF, linearity was assessed
within the range of 10–320 ng/mL. For precision, the RSD
was <15% and the relative error (RE) of accuracy was less
than 15%.
2.3.2. ABZ-SO assay in plasma
Plasma levels of ABZ-SO were determined by a liquid
chromatography-mass spectrometry (LC-MS) method. The
LC-MS system consisted of a Finnigan Surveyor LC pump
Plus and a Finnigan Surveyor autosampler Plus coupled to a
Finnigan LCQ Advantage Max ionic trap mass spectrometer
(Thermo Electron Corporation, San Jose, CA, USA). Chro-
matographic separation was performed using a Gemini C18
analytical column (150  4.6 mm, 5 lm, Phenomenex, Tor-
rance, CA, USA) protected with a pre-column (Phenomenex
C18 ODS). The mobile phase was composed of methanol:-
formic acid 20 mM (70:30, v/v) at a 0.7 mL/min flow rate with
a split ratio of 1:3. Compounds eluting from the column were
analyzed in the positive ion mode, with 3.5-kV capillary volt-
age. Nitrogen was employed as sheath gas (23 arb) and auxil-
iary gas (4 arb). The heated capillary temperature was set at
290 C. Quantitation was performed using selected reaction
monitoring (SRM) of the transitions of m/z 282? 240 for
ABZ-SO and of m/z 296? 264 for MBZ (IS). The collision
energies of 25 and 32 eV were used for ABZ-SO and IS,
respectively.
A volume of 200 lL of plasma sample was transferred into
an assay tube and spiked with 100 lL of 400 ng/mL IS in
methanol. After the addition of 4.5 mL of ether-dichlorome
thane-chloroform (60:30:10, v/v/v), samples were vortex-
mixed for 5 min and centrifuged for 30 min at 1408g. The
supernatant was transferred to a clean glass-assay tube and
evaporated to dryness in a water bath at 45 C with a nitrogen
stream. The residue was reconstituted with 160 lL of metha-
nol:water (70:30 v/v), and a 25 lL aliquot was injected into
the chromatographic system. Linearity for ABZ-SO in plasma
was assessed within the range of 20–3000 ng/mL. Calibration
curves were plotted using ABZ-SO area/IS area vs. concentra-
tion and analyzed by 1/x weighted least-squares linear regres-
sion. Correlation coefficient was P0.998. The method was
precise (RSD, <8%) and accurate (RE, <8%).
2.3.3. ABZ-SO assay in CSF
ABZ-SO in CSF levels was determined by HPLC. A 20 lL ali-
quot of CSF was injected directly into the chromatographic
system, which consisted of a Waters Alliance 2690 HPLC
pump (Waters) coupled to a photodiode array detector (Model
2296 Waters) set at 293 nm and a Model 2690 Waters Alliance
autosampler. Separation was performed using an Atlantis T3
analytical column (150  1 mm, 3.5 lm; Waters) protected
with a pre-column (Phenomenex C18 4 mm  3 mm; Phenom-
enex). The autosampler and column oven were set at 15 and
30 C, respectively. For mobile phase, a gradient was
employed as depicted in Table 1. The flow rate was set at
0.06 mL/min. The method was linear within the range of 10–Please cite this article in press as: Ruiz-Olmedo, M.I. et al., Eﬀect of nitazoxanide on
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.09.0051500 ng/mL with correlation coefficients of P0.99. The
method was precise (RSD, <1%) and accurate (RE, <14%).
2.4. Pharmacokinetic and statistical analysis
Plasma and CSF concentration-time data were analyzed by a
non-compartmental model using WinNonLin ver. 5.0 software
(Pharsight Corp., Mountain View, CA, USA). Peak plasma
concentration (Cmax), time to reach peak plasma concentra-
tion (Tmax), area under the curve (AUC) to the last measur-
able plasma concentration point (AUC0?t), elimination half-
life (t1/2), and mean residence time (MRT) were calculated.
Results are expressed as mean ± standard error of the mean
(SEM). Statistical analysis was assessed by the Student t test.
Differences were considered statistically significant at
p< 0.05.
3. Results and discussion
3.1. Study 1
When the pharmacokinetics of NTZ was evaluated, we found
that, as expected, TZO was the only measurable species in
plasma (Fig. 1). TZO reached a maximum plasma concentra-
tion (Cmax) of 244.42 ± 31.98 ng/mL at 0.25 h. This low
plasma concentration could be related to incomplete absorp-
tion of NTZ from the gastrointestinal tract (Huang et al.,
2015).
With respect to the pharmacokinetic parameters of NTZ,
we found that plasma elimination half-life was short (1.47 h)
and similar to that reported in humans (1.53 h) (Stockis
et al., 1996). Moreover, MRT was also short (1.27 ± 0.17 h).albendazole pharmacokinetics in cerebrospinal ﬂuid and plasma in rats. Saudi
Effect of nitazoxanide on albendazole pharmacokinetics 5Cmax and AUC showed a low interindividual variability (%
RSD: 13 and 26, respectively).
When CSF samples were analyzed, TZO was undetectable
at nearly all sampling times. The metabolite was detected only
at 0.5 h; however, TZO levels were below the quantification
limit (10 ng/mL). To date, to our knowledge, brain permeation
of TZO has not been reported. Our results suggest low access
of the metabolite into the brain. The low permeation could be
related to the low levels of TZO in plasma or its short elimina-
tion half-life. Considering that only the unbound plasma frac-
tion can freely penetrate to CSF, another possibility could be
associated with TZO’s high protein binding (98%) (Zhao
et al., 2010).
3.2. Study 2
The results of our study revealed that in rat, ABZ was rapidly
metabolized to its main active metabolite: ABZ-SO. As in
humans, ABZ-SO also crossed the BBB and reached the
CSF. In this fluid, the metabolite was detected from the first
sampling time and during the entire interval (16 h). Fig. 2 pre-
sents ABZ-SO profiles in plasma and in CSF, and Table 2
summarizes the main plasma and CSF pharmacokinetic
parameters.
When ABZ was administered alone, a great inter-individual
variability in plasma levels was found (Fig. 2). The absorption
process was slow: ABZ-SO maximum concentration was
reached at 6.8 h. Tmax and MRT values were similar to those
reported by Merino et al. (2003) after the administration of a
10.6 mg/kg dose of ABZ in the same species. When ABZ-SOTable 2 Non-compartmental pharmacokinetic parameters for ABZ
ABZ and 15 mg/kg plus 7.5 mg/kg NTZ (mean ± SD, n= 5).
Parameter ABZ
Plasma CSF
Cmax (ng/mL) 1729.30 ± 1190.76 170.40 ± 79
Tmax (h) 6.80 ± 3.63 8.40 ± 3.85
AUC (ng h/mL) 16371.40 ± 7125.28 1885.23 ± 8
t1/2 (h) 2.53 ± 0.65 4.16 ± 1.27
MRT (h) 7.40 ± 0.62 8.36 ± 0.89
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Figure 2 Albendazole sulfoxide plasma and CSF concentration
time profile after an oral dose of 15 mg/kg albendazole and after
an oral dose of 15 mg/kg albendazole and 7.5 mg/kg nitazoxanide.
Each point represents the mean ± SD, n= 5.
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pared, we found that Tmax and MRT were similar.
When ABZ was administered in combination with NTZ we
found that, although plasma levels at 8 and 10 h after admin-
istration were slightly higher in comparison with the adminis-
tration of ABZ alone, the differences were not significant. In
the case of CSF, ABZ-SO levels were also higher in the com-
bined treatment without statistical significance. Likewise, no
statistical differences were found in MRT in plasma and in
CSF between both treatments. These results indicate that
under the study conditions, NTZ did not markedly modify
ABZ pharmacokinetics.
In a previous study in mice, it was found that the combined
treatment of NTZ and ABZ increased ABZ-SO serum levels
during the 4–8 h interval after administration. The authors
suggested that the uptake of one drug affected the absorption
of the other drug (Stettler et al., 2004).
Taking these results into account, we expected an increase
in ABZ-SO levels in plasma and also in CSF. The lack of phar-
macokinetic interaction found in the present study could be
associated with the following factors which might influence
the solubility and bioavailability of one or both drugs: (a)
The doses administered, as the doses of ABZ and NTZ
employed in the present study were 15 mg/kg plus 7.5 mg/kg,
while the doses used by Stettler et al. were 33 mg/kg plus
150 mg/kg; (b) The dosage form. While in our study commer-
cial suspensions of ABZ and NTZ were employed, Stettler
et al. used the pure drugs suspended in 0.5% carboxymethyl-
cellulose, and (c) the differences in the animals’ species used.
It has been reported that the fluid content in the gastrointesti-
nal tract in mice is smaller than that found in rats (McConnel
et al., 2008).
Few studies have been performed to evaluate pharmacoki-
netic interactions of NTZ with other anthelminthic drugs. In
2015, Ceballos et al. (2015) evaluated the combination of
flubendazole and NTZ in mice. As in our study, authors found
that NTZ did not significantly affect the efficacy and pharma-
cokinetics of flubendazole.4. Conclusion
Since tizoxanide (the active metabolite of nitazoxanide) did not
cross the blood brain barrier and that plasma and cere-
brospinal fluid levels of albendazole sulfoxide (the active
metabolite of albendazole) were also not markedly affected
by tizoxanide, the combination of albendazole and nitazox-
anide would not be a suitable alternative for neurocysticercosis
treatment.-SO in rat plasma and CSF after oral administration of 15 mg/kg
ABZ plus NTZ
Plasma CSF
.22 2124.35 ± 871.18 466.94 ± 312.37
9.60 ± 0.89 8.40 ± 2.97
32.47 19301.31 ± 8690.05 3892.51 ± 2178.37
2.25 ± 0.55 3.73 ± 1.66
8.15 ± 0.39 7.67 ± 0.67
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